GLAUKOS Corp (GKOS)
Glaukos develops and sells eye treatments, including glaucoma stents and drug implants, for ophthalmologists and other eye care professionals. It last closed at $243.34 on Nov 17, down 0.65% on the day. GKOS last reported earnings on Wed, Oct 28, 2026. The average 12-month price target from 10 analysts is $239.40 (-1.6% from the last close), with a high of $255.00 and a low of $210.00. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (10 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in GKOS, 71% of them bullish and 29% bearish. In the past 30 days there were 5 dark pool prints totaling $6.8M, the largest $2.4M.
Key Stats
Last 12 monthsNot reported for this period.
From GKOS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 28). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 10 analysts who set a price target on GKOS in the past 90 days. The average target is $239.40, with a high of $255.00 and a low of $210.00, compared with the last close of $243.34.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | BTIG | Target raised | Buy | $234 → $252 |
| Oct 29 | HC Wainwright & Co. | Target raised | Buy | $195 → $248 |
| Oct 29 | JP Morgan | Maintained | Buy | $240 |
| Oct 29 | Citigroup | Target raised | Buy | $188 → $247 |
| Oct 29 | Truist Securities | Target raised | Buy | $215 → $255 |
Technical Analysis
The stock is 9% above its 20 day and 23% above its 50 day average. It is 39% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 67), near overbought. The nearest support is the Pivot S1 at $239.75, and the nearest resistance the Pivot at $243.40.
| RSI (14) | 66.87 | Strong, overbought above 70 | Neutral |
| MACD | 18.25 | Above its signal line | Bullish |
| Stochastic | 83.6 | Near the top of its range | Overbought |
| ADX (14) | 42.6 | Strong uptrend | |
| Williams %R | -24.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 59.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +4.4% | Change over 10 sessions | Bullish |
| ATR (14) | $11.29 | Typical daily range, 4.6% of price |
| RSI (14) | 73.57 | Overbought above 70 | Overbought |
| MACD | 24.38 | Above its signal line | Bullish |
| Stochastic | 84.0 | Near the top of its range | Overbought |
| ADX (14) | 35.3 | Trending up | |
| Williams %R | -10.9 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 193.4 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +45.5% | Change over 10 sessions | Bullish |
| ATR (14) | $20.29 | Typical daily range, 8.3% of price |
What happened before
See how GKOS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GKOS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in GKOS in the last 90 days.
Dark Pool
30DGKOS Institutional Ownership
Full report →- ▲230 buying vs 176 selling
- ▼Held by funds -2.6 pts
- ▲Funds holding +54
- ▲Superinvestors: 3 added, 2 cut
- ▼Put/call 2.12 to 2.67
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 422 | 368 | +14.7% |
| In funds' top 10 | 5 | 2 | +150.0% |
| Held by funds | 100.3% | 102.9% | −2.6 pts |
| New / increased | 89 / 141 | 68 / 147 | +7.0% |
| Reduced / sold out | 141 / 35 | 101 / 39 | +25.7% |
| Put/call ratio | 2.67 | 2.12 | +25.9% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GKOS is in one of them and how their past GKOS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GKOS in an article yet. Here's the latest on the wider market.
GKOS Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Sell | $50K – $100K | Jul 29, 2026 | Sep 22, 2026 | 55 d |
| Donald J TrumpExecutive branch | Sell | $15K – $50K | May 15, 2026 | Jul 1, 2026 | 47 d |
| Donald J TrumpExecutive branch | Buy | $15K – $50K | Mar 30, 2026 | May 14, 2026 | 45 d |
| Donald J TrumpExecutive branch | Other | $1K – $15K | Feb 26, 2026 | May 14, 2026 | 77 d |
| Donald J TrumpExecutive branch | Buy | $15K – $50K | Jan 26, 2026 | May 14, 2026 | 108 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About GLAUKOS
Glaukos is an ophthalmic pharmaceutical and medical technology company based in Aliso Viejo, California. It makes procedural treatments for glaucoma, including small stents placed during eye surgery and a drug implant that releases medication inside the eye over time. It also sells treatments that strengthen the cornea for corneal disorders such as keratoconus, and it is developing therapies for retinal disease. Its customers are ophthalmologists and other eye care professionals.
- Headquarters
- Aliso Viejo, CA





